Lamivudine (salicylate)

Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI) . Lamivudine salicylate can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].

Product Specifications

CAS Number

[173522-96-8]

Product Name Alternative

BCH-189 (salicylate)

UNSPSC

12352005

Hazard Statement

H361-H373

Target

HBV; HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/lamivudine-salicylate.html

Solubility

10 mM in DMSO

Smiles

OC[C@H]1SC[C@@H](N2C(N=C(N)C=C2)=O)O1.OC3=C(C(O)=O)C=CC=C3

Molecular Formula

C15H17N3O6S

Molecular Weight

367.38

Precautions

P260-P280-P405-P501

References & Citations

[1]Li, Y.C., [A clinical study on lamivudine treatment for advanced schistosomisis with chronic B hepatits]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi, 2013. 25 (5) : p. 548-9, 551.|[2]Zhang, C.E., et al., [Effects of lamivudine on growth of intestinal characteristic bacteria by microcalorimetry in vitro]. Yao Xue Xue Bao, 2013. 48 (10) : p. 1590-4.